ǰÑÔ
Ö¬·¾¸Î(fatty liver disease,FLD)ÊÇÖ¸ÓÉÓÚÖÖÖÖÔµ¹ÊÔÓÉÒýÆðµÄ¸ÎÔàÖ¬·¾´úлÕϰ£¬Ö¬ÀàÎïÖʵĶ¯Ì¬Æ½ºâʧµ÷£¬¸Îϸ°ûÄÚÖ¬·¾Èº¼¯¹ý¶àµÄ²¡±ä¡£Ö¬·¾¸ÎµÄ·¢²¡ÂʽüÄêÀ´Ñ¸ËÙÉÏÉý£¬ÒѳÉΪ½ö´ÎÓÚ²¡¶¾ÐÔ¸ÎÑ׵ĵڶþ´ó¸Î²¡£¬ÕýÑÏÖØÍþв¹úÈ˵Ŀµ½¡¡£Æ¾Ö¤²¡Òò£¬Ö¬·¾¸Î¿É·ÖΪ·Ç¾Æ¾«ÐԺ;ƾ«ÐÔÁ½´óÀà¡£·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡(nonalcoholic fatty liver disease, NAFLD)·¢²¡»úÖÆÏÖÔÚÉÐδÃ÷È·£¬ÖÎÁÆÉÏҲȱ·¦ÓÐÓò½·¥£¬ÊÇÏÖÔÚÑо¿µÄÖØµã¡£¾Æ¾«ÐÔÖ¬·¾¸Î¶¯ÎïÄ£×ÓÒÔÒûʳÓÕµ¼ÎªÖ÷£¬¾Æ¾«¿Éʹ¶¯Îï¸ÎÔàÑõÏûºÄÂÊÔö¸ß£¬ÔöÌíѪñ¼ÑªµÄÑõÏûºÄ£¬´Ó¶øïÔ̶ÔСҶÖÐÐĸÎϸ°ûµÄÑõ¹©£¬ÒýÆð¸ÃÇøÓòµÄ¸Îϸ°ûÍË»¯Ó뻵ËÀ£¬²¢±¬·¢Ö¬·¾±äÐÔ¡£ÀíÏëµÄÖ¬·¾¸Î¶¯ÎïÄ£×ÓÓ¦ÓëÈËÀàÖ¬·¾ÐԸβ¡µÄÌØÕ÷ÏàËÆ£¬¼´²¡±äÉú³¤Àú³ÌÓÐÏà¶ÔÏÔ×ÅµÄ·ÖÆÚ£¬´Ó´¿´âÐÔÖ¬·¾¸Î¡¢Ö¬·¾ÐÔ¸ÎÑס¢¸ÎÏËά»¯ÖÁ¸ÎÓ²»¯£¬²¢ÇÒÓ¦¾ßÓÐÄ£×ÓÐγÉÂʸߡ¢éæÃüÂʵ͡¢ÔìÄ£ÒªÁìÇáÓ¯Ò×ÐС¢¶ÔʵÑéÖ°Ô±ÎÞº¦¡¢ÔìÄ£×èÖ¹ºó²¡±äÄæ×ª»ºÂý£¬±ãÓÚ¾ÙÐÐÒ©Îï¸ÉÔ¤ÊÔÑéµÈÌØµã¡£ÏÖÔÚÒѾÔÚ´óÊó¡¢É³Êó¡¢Ð¡Êó¡¢¼ÒÍúÍÖíµÈ¶¯ÎïÖÖÊôÀֳɵؽ¨ÉèÁËÖ¬·¾¸Î¶¯ÎïÄ£×Ó£¬ÕâЩ¶¯ÎïÄ£×ÓΪÃ÷È·Ö¬·¾¸Î·¢²¡»úÖÆ¡¢É¸Ñ¡Ò©ÎïµÈ»ù´¡ºÍÁÙ´²Ñо¿ÌṩÁ˺ܺõÄʵÑ鹤¾ß¡£
FLD¶¯ÎïÄ£×ÓÖ÷Òª·ÖΪËÄ´óÀࣺ×Ô¾õÐÔÄ£×Ó£¬»ùÒòÐÞÊζ¯ÎïÄ£×Ó£¬Òûʳ¡¢Ò©Îï»ò¶¾ÎïÓÕµ¼Ä£×Ó£¬¸´ºÏÄ£×Ó£¨ÍŽáÓ¦ÓûùÒòÄ£×ÓºÍÓªÑøÄ£×Ó£©¡£ËüÃÇÔÚ²î±ðµÄ²ãÃæÊ©Õ¹×÷Ó㬵«×îÖÕÖ÷ÒªÊÇͨ¹ýʹ¸ÎÔàÖ¬·¾ÊäÈ루ºÏ³É»òÉãÈ룩ÔöÌí»òÊä³ö£¨É¨³ý£©ïÔ̵ÄÔÀíÖÆ³É¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯ÎСÊó
¡¾ÔìÄ£ÒªÁì¡¿£º
ÍŽáʹÓûùÒòÐÞÊκÍÓªÑøÒòËØ¿É±¬·¢¸üÇкÏÈËÀàNAFLD·¢²¡¼ÍÂɵ͝ÎïÄ£×Ó£¬ È磺ob/obСÊó£«MCDÒûʳ¡¢db/dbСÊó£«MCDÒûʳ¡¢Abcb11СÊó£«MCDÒûʳ¡¢ApoE-/-СÊó£«HFD¡¢PPARα-/-СÊó£«MCDÒûʳµÈ¡£
¡¾Ä£×ÓÌØµã¡¿£º
¸´ºÏÄ£×Ó¾ù¿É±¬·¢ÒȵºËضԿ¹¡¢·ÊÅÖÒÔ¼°Ö¬·¾ÐÔ¸ÎÑ׺ÍÏËά»¯¡£ÆäÖÐdb/dbСÊó£«MCDÒûʳģ×Ó±Èob/obСÊó£«MCDÒûʳģ×ÓÑ×Ö¢¼°Ï¸°ûÖܸÕÏËά»¯¸üÑÏÖØ£¬²¡±ä·ºÆðʱ¼äÏÔ×ÅËõ¶Ì£¬²¢ÇÒ°é·ÊÅÖ¡¢¸ßÒȵºËØÑªÖ¢¼°¸ßÊÝËØÑªÖ¢ÎÄPPARα-/-СÊó¾MCDÒûʳÓÕµ¼ºó·ºÆð½Ï±ÈÕÕ×é¸üÏÔÖøµÄNAFLDÌåÏÖ¡£
¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º
ÏÖÓж¯ÎïÄ£×ӵIJ¡Àí¸Ä±äºÍ·¢²¡»úÖÆÒòÔìÄ£ÒªÁì²î±ð¶øåÄÒ죬ÉÐÎÞÒ»ÖÖÄ£×ÓÄÜÖÜÈ«ÏÔʾÈËÀàFLD²¡Àí¸Ä±äºÍ²¡ÀíÐÄÀíµÄÀú³Ì¡£»ùÒòÐÞÊÎÄ£×ÓÖлùÒò¸Ä±äÄܹ»ÒýÆðÖ¬·¾´úлÔÓÂÒºÍÑõ»¯Ó¦¼¤£¬µ«ÈËÀàNAFLDÖ÷ÒªÓëÒÅ´«Ò׸ÐÐÔºÍÒȵºËضԿ¹Óйأ¬²¢ÇÒ»ùÒòÐÞÊÎÒ×ÓÚ±¬·¢HACºÍHCC£¬¿ÉÄܸüÊʺÏÑо¿NAFLDÏà¹ØHCCµÄ»úÖÆ¡£ÓÉÓÚÖÁ½ñûÓÐÆÊÎö¹ý¶àÉãÈëʳÎïÊÇÔõÑùÒýÆðÖ¬·¾¸Î£¬Ò²²»ÇåÎúʳÎïÖкÎÖÖÒòËØ×îÈÝÒ×ÒýÆð·ÊÅÖºÍÖ¬·¾¸Î£¬²¢ÇÒºÜÄÑ¿ØÖÆÈËÀà»ìÏý±£´æµÄµ÷ÀíÄÜÁ¿´úлµÄËùÓÐÒÅ´«ºÍÇéÐÎÒòËØ¡£Òò´Ë£¬µ÷¿Ø¶¯ÎïÄ£×ÓµÄʳÎï×é³ÉºÍʳÎïÉãÈëÊÇÑо¿ÒûʳÔÚ·ÊÅÖÏà¹ØÖ¬·¾¸ÎµÄ½ÏºÃÒªÁ졣Ȼ¶ø£¬²î±ðÆ·ÖÖ¡¢ÄêËêºÍÐÔ±ðµÄÄö³Ý¶¯Îï¶ÔÒûʳÓÕµ¼µÄ·ÊÅÖºÍÖ¬·¾¸Î±£´æ×ÅÒ»¶¨²î±ð£¬ÈçMCDÄ£×ÓµÄÑÏÖØË®Æ½¼°ÆäÏ£ÍûËÙÂÊÒÀÀµÓÚʵÑ鶯ÎïµÄÐÔ±ð¡¢Æ·ÏµºÍÖÖÀà¡£¸´ºÏÄ£×Ó×îºéÁ÷ƽµØÄ£ÄâÁËÈËÀàNAFLDµÄÖØ´óÐÔ£¬²¡Àíת±äÏÔÖø£¬ÊÇÒ»ÖÖ¼«¾ßDZÁ¦µÄÄ£×Ó¡£
Ñо¿ÕßӦƾ֤Ñо¿Ä¿µÄ¡¢ÊÖÒÕÊìÁ·Ë®Æ½ºÍËùÔÚʵÑéÊÒµÄÌõ¼þ£¬Ñ¡ÔñºÏÊʵ͝ÎïÄ£×Ó£¬ËùÑ¡¶¯ÎïÄ£×ÓÓ¦ÓëÑо¿Ä¿µÄÏà·û£¬ÇÒÄ£×ӵĸ´ÖÆÂʸߣ¬ÈçÉÏÊöob/obºÍdb/dbСÊóÊÇʵÑéÊÒ³£ÓõÄÑо¿´úлÏà¹Ø¼²²¡µÄ¹¤¾ßÊó£¬Ó¦ÓÃÆÕ±é£¬ÈÝÒ×»ñµÃ¡£»¹Ó¦Í¨¹ý´¿Ïµ¶¯ÎïµÄ×÷Óý¼°ÓªÑøÒûʳÅä·½µÄ¸ÄÁ¼µÈÒ»Ö±¸ÄÁ¼ÔìÄ£ÒªÁ죬²¢ÊµÊ±½«ÐÂÊÖÒÕ¡¢ÐÂÒªÁìÓëÐÂÖ¸±êÓÃÓÚ¶¯ÎïʵÑé¡£
²Î¿¼ÎÄÏ×£º
1.Ê©ÐÂé࣮ÏÖ´úҽѧʵÑ鶯Îïѧ£®±±¾©£ºÈËÃñ¾üÒ½³öÊéÉ磬2000
2.Farrell GC, van Rooyen D. Liver cholesterol: is ii playing possum in NASH? Am J Physiol Gastroinlesl Liver Physiol,2012,303 (1):G9-11
3.Maher JJ. New insights from rodent models of fatly liver disease. Anliox.id Redox Signal, 2011, 15 (2):535-550
4.Matsuzawa N,Takamura T, Kurita S, el al. Lipid-induced oxidative stress causes sleatohepalitis in, mice fed an atherogenic diet. Hepatology, 2007,46 (5):1392-1403
5.Sahai A, Malladi P, Pan X, el al. Obese and diabeti db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepalitis: role of sbortform leptin receptors and osteopontin. Am J Physiol Gastroinlest Liver Pbysiol, 2004,287 (5):Gl035-1043
6.Uno M, Kurita S, Misu H,et al. Tranilast,an anlifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepalitis. Hepatology, 2008, 48 (1) : 109-118
7.Xu Z,Chen L,Leung L,el al. Liver-specific i.naclivalion of the Nrfl gene in adult mouse leads lo nonalcoholic steatobepatilis and hepatic neoplasia. Proc Natl Acad Sci US A, 2005, 15; 102 (11):4120-4125